The landscape after PEACE: do all ACE inhibitors act in an identical way?

Author: Grajek, Stefan¹

Source: Current Medical Research and Opinion, Volume 22, Number 2, February 2006 , pp. 265-274(10)

Publisher: Informa Healthcare

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Abstract:

The results of the Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE trial), involving patients with stable coronary heart disease, demonstrated that the angiotensin-converting enzyme (ACE) inhibitor trandolapril did not reduce cardiovascular mortality, or the incidence of fatal or non-fatal myocardial infarction. These results were in conflict with the vast majority of previously published large-scale trials, and could be seen to weaken confidence in ACE inhibitor therapy of ischaemic heart disease.

This review article examines the results of PEACE in comparison with the other major trials in terms of the severity of the disease in the patients, the statistical power of the analyses, the doses of the agents used and the concept of a 'class effect' of the ACE inhibitors.

Keywords: ACE INHIBITORS; CLASS EFFECT; ISCHAEMIC HEART DISEASE; MYOCARDIAL INFARCTION, FATAL, NON-FATAL; PEACE TRIAL

Document Type: Commentary

DOI: 10.1185/030079906X80512

Affiliations: 1: Department of Cardiology, Karol Marcinkowski University of Medical Science, Poznań, Poland

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$51.50 plus tax Refund Policy